Treg engineers take aim at autoimmunity
Elie Dolgin • Nov 09, 2021
Companies are deploying regulatory T cells, equipped with CAR and TCR constructs, to suppress immunity — locally and for the long term.
Engineered adoptive T-cell therapies have already transformed the treatment of blood cancers. Now, several startups hope to harness the power of regulatory T cells (Tregs) to suppress immune responses and offer tolerance to transplant recipients, or to control the inflammation driving autoimmune disorders.
Continue reading at Nature Biotechnology.
Drug trial results show that vaccines aren't the only use for the mRNA technology behind the most widely used COVID-19 jabs.
FDA panel’s green light on glaucoma wearable device offers hope in sight.